Orgenesis to Present at the 2013 Gateway Conference on September 10
SAN FRANCISCO, CA, Sep 04, 2013 (Marketwired via COMTEX) --
Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a
novel therapeutic technology dedicated to converting a patient's own
liver cells into functioning insulin-producing cells as a treatment
for diabetes, has been invited to present at the 2013 Gateway
Conference being held on Tuesday, September 10, 2013 at the Palace
Hotel in San Francisco.
Orgenesis CEO Sav DiPasquale is scheduled to present at 12:00 p.m.
Pacific time, with one-on-one meetings held throughout the day. The
presentation will also be webcast live and available for replay at
www.gateway-conference.com, under the Presenting Companies tab.
For additional information or to schedule a one-on-one meeting visit
www.gateway-conference.com and click on the Register/Login tab. You
may also email your request to firstname.lastname@example.org or
call Justin Vaicek at (949) 574-3860.
About the Gateway Conference
The Gateway Conference is designed to
provide a unique gateway between influential members of the
investment community and a select group of compelling publicly-traded
companies. Portfolio managers, research analysts and brokers from
buy-side and sell-side institutions will have the opportunity to
learn about more than 50 exciting growth companies across a broad
range of industries, from technology, business and financial
services, digital media and clean-tech to consumer products,
retail/e-commerce, life sciences and natural resources. For more
information, visit www.gateway-conference.com.
The invitation-only conference is hosted by Liolios Group, one of the
nation's top investor relations agencies, and sponsored by leading
firms that service the financial community. For more information
about Liolios Group, visit www.liolios.com.
About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company
with a novel therapeutic technology that employs a molecular and
cellular approach directed at converting a patient's own liver cells
into functional insulin producing cells, as a treatment for diabetes.
The Company believes that converting the diabetic patient's own
tissue into insulin-producing cells overcomes the problem of donor
shortage and removes the risk of transplant rejection. If successful,
this could mean the end of diabetes, as we now know it. For more
information visit: www.orgenesis.com.
Liolios Group, Inc.
Tel (949) 574-3860
SOURCE: Orgenesis Inc.
[ Back To Technology News's Homepage ]